The results showed overall high concordance between test results and whether patients received chemotherapy, with some relevant exceptions.
The Nuffield Council report is the first step in addressing ethical considerations of genome editing in human health, food, and the natural environment.
The bill comes amid questions about the efficacy of Epigenomics' Epi proColon, the only blood-based cancer screening test approved in the US.
The bill, which would boost NIH funding among other things, was overwhelmingly approved by the House and cleared a Senate subcommittee, but has stalled amid negotiations over appropriations.
The committee questioned stakeholders about the impact of FDA oversight of LDTs, and whether there was any consensus about how to move forward on a divisive topic.
Despite recent bills that argue the advent of NIPS will increase abortion, researchers say that there is not yet enough data.
Tufts scientists and their colleagues called for steps to ensure that disadvantaged groups benefit from genetically based diagnoses and treatments.
The Senate will not act on its companion to the House-backed biomedical research funding bill before its summer recess, its health committee chairman said.
The House bill would boost the NIH's budget 4 percent to $33.3 billion, but the increase is less than that recommended by the Senate last month.
The Institute for Clinical and Economic Review is seeking public comment on its plan to evaluate the cost-effectiveness of EGFR inhibitors and immunotherapies.
The investment, which will be paid out over the course of five years, comes in part from industry sources.
A member of the committee issuing a blunt report on the inadequacy of biomarker-based testing speaks about what the next Secretary of HHS needs to do.
The researchers will receive $2 million over three years to study the legalities of translating genomic medicine into clinical applications.
The proposed bill would provide the agency with a $2 billion budget increase for the second year in a row after more than a decade of stagnant funding.
EEOC final rules provide employers clarity on wellness programs, but they may confuse the public about genetic privacy and anti-discrimination laws, some groups said.
Four patients still want the government to investigate their allegations against Myriad, even though the firm complied with their data request at the last hour.
According to ASHG, the final rules, issued this week, will significantly weaken patient privacy protections under ADA and GINA.
Williams is within the time frame in which she can sue, her lawyers maintain, since she didn't know about the lab's "mistake" until last year.
Only 5 percent of respondents said they got tested through a consumer genomics firm, but the future market could be worth as much as $7 billion, analysts at UBS estimated.
Collins did not weigh in on the debate over mandatory versus discretionary budgets, but said that a reduction in NIH funding would be devastating.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.